Product information and disease descriptionPlace of product in therapyDisease description
Pathophysiology
5 evidence topics · 4 sources
Overview: barrier disruption, dysbiosis, and abnormal mucosal immune activation
“A widely accepted framework suggests a complex contribution of environmental and host factors that increase the susceptibility of developing UC, and disease onset is triggered by events that perturb the mucosal barrier, alter the healthy balance of the gut microbiota, and abnormally stimulate gut immune responses.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Ulcerative colitis is thought to occur in people with a genetic predisposition following environmental exposures; gut epithelial barrier defects, the microbiota, and a dysregulated immune response are strongly implicated.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Mucosal inflammation: continuous from the rectum and limited to the mucosa
“These clinical features include the almost-universal involvement of the rectum (the lowest part of the colon) as the first site where inflammation starts and the distinctively confluent nature of inflammation that ends with an abrupt demarcation and transition into normal colonic mucosa.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Epithelial barrier: impaired barrier and UC-specific epithelial susceptibility genes
“An impaired epithelial barrier is a pathogenic factor for UC” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“UC-specific genes implicate epithelial dysfunction” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“With the histologic observation of subepithelial inflammation, many studies implicate an impaired epithelial barrier as a pathogenic factor for UC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Microbiota: reduced diversity and loss of short-chain fatty acid producers
“The UC gut microbiome, virome, and mycobiome is less diverse over time” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“A depletion of protective bacteria such as short-chain fatty acid (SCFA)-producing Ruminococcaceae and Lachnospiraceae that coincides with an expansion of pro-inflammatory microbes such as Enterobacteriaceae, including Escherichia coli, and Fusobacteriaceae has been noted 37, 38.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“It is not known if dysbiosis is a consequence of, or plays a causal role in, gut inflammation in UC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Immune response: innate activation, atypical Th2 response, and IL-23 and Th17 pathways
“Innate immune responses (neutrophils/macrophages) may promote a pathogenic adaptive (likely T-cell driven) response” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Traditionally, UC is associated with a Th2 response with high IL-4, IL-5, and IL-13, whereas CD has a more dominant Th1/Th17 response 84.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“These include the identification of IL-23 as a key driver of Th17 responses 86, genetic associations with IL-23 and its related genes 11, 87, and the presence of Th17 88 (and Th9 89) cells in UC.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Blocking IL-23, however, is effective in UC, e.g. mirikizumab (anti-p19 subunit of IL-23) 92 and ustekinumab (anti-p40 subunit of IL-23) 93.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote